Back to Journals » Drug Design, Development and Therapy » Volume 12

Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?

Authors Yasar U

Received 27 March 2018

Accepted for publication 3 May 2018

Published 11 July 2018 Volume 2018:12 Pages 2169—2172


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Georgios D. Panos

Umit Yasar

Department of Medical Pharmacology, Hacettepe University, Faculty of Medicine, Ankara, Turkey

He et al have reported inhibitory effect of celecoxib on agomelatine metabolism in rat/human liver microsomes, recombinant human cytochrome P450 (CYP) 2C9 in vitro and in Sprague Dawley rats in vivo.1
I would like to emphasize two important points related to celecoxib–agomelatine interaction. Firstly, according to an article cited by He et al written by Liu et al, refers to the metabolism of agomelatine, CYP1A2 and CYP3A4 are the major CYP enzymes but not CYP2C9.2 In that study, Liu et al characterized novel metabolic pathways and CYP-mediated metabolism of agomelatine using metabolomic approaches.2 Among the 39 metabolites of agomelatine determined, 19 have been produced by CYP enzymes, mainly by CYP1A2. He et al cited another review article written by Sansone and Sansone as a reference to the role of CYP2C9 in the metabolism of agomelatine; however, that article also indicated CYP1A2 as the main responsible enzyme for agomelatine metabolism, and nothing was mentioned about the contribution of CYP2C9.3 In earlier in vitro studies and the European Medicines Agency assessment report, CYP1A2, CYP2C9 and CYP2C19 have been suggested as the enzymes responsible for the metabolism of agomelatine. These in vitro data should be carefully interpreted because the type of in vitro drug metabolism system and the concentrations of the drug used in those studies may not directly be correlated with in vivo conditions. For example, in He et al, inhibitory effect of celecoxib was not present at 10 μM and was observed at 50 μM in liver microsomes and this inhibition pattern does not reflect in vivo conditions.1 Therefore, considering the findings in literature, the contribution of CYP2C9 in agomelatine metabolism seems to be minor and needs to be clarified in further studies. 
View the original paper by He and colleagues. 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]